Sanofi/Oxford BioMedica To Present Positive Phase II Data For Cancer Vaccine TroVax At ASCO

 
• By Brooke McManus

Oxford BioMedica anticipates filing a BLA in 2009 for RCC.

More from Archive

More from Pink Sheet